Unknown

Dataset Information

0

Ipilimumab: from preclinical development to future clinical perspectives in melanoma.

ABSTRACT: The arsenal for the treatment of metastatic melanoma is limited. A new approach to therapy using checkpoint blockade has improved overall survival in this patient population. Ipilimumab a CTLA-4 monoclonal antibody is a first in class drug that has pioneered this revolution. In this review, the authors provide an account of the different stages that led to the development of ipilimumab, its approval in the clinical setting for the treatment of advanced melanoma and ongoing investigations of combinatorial immune therapy.

SUBMITTER: Letendre P 

PROVIDER: S-EPMC5618953 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Ipilimumab: from preclinical development to future clinical perspectives in melanoma.

Letendre Paul P   Monga Varun V   Milhem Mohammed M   Zakharia Yousef Y  

Future oncology (London, England) 20161124 7

The arsenal for the treatment of metastatic melanoma is limited. A new approach to therapy using checkpoint blockade has improved overall survival in this patient population. Ipilimumab a CTLA-4 monoclonal antibody is a first in class drug that has pioneered this revolution. In this review, the authors provide an account of the different stages that led to the development of ipilimumab, its approval in the clinical setting for the treatment of advanced melanoma and ongoing investigations of comb  ...[more]

Similar Datasets

Unknown Cancer DNA vaccines: current preclinical and clinical developments and future perspectives.
| S-EPMC6449928 | biostudies-literature
Unknown Patient perspectives on ipilimumab across the melanoma treatment trajectory.
| S-EPMC5651412 | biostudies-literature
Unknown Osteochondral tissue engineering: Perspectives for clinical application and preclinical development
| S-EPMC8517716 | biostudies-literature
Unknown Checkpoint modulation in melanoma: an update on ipilimumab and future directions.
| S-EPMC3799873 | biostudies-literature
Unknown Intraperitoneal Chemotherapy for Peritoneal Metastases: Technical Innovations, Preclinical and Clinical Advances and Future Perspectives.
| S-EPMC8001167 | biostudies-literature
Unknown Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.
| S-EPMC5828774 | biostudies-other
Unknown Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives.
| S-EPMC5874676 | biostudies-literature
Unknown Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.
| S-EPMC4336189 | biostudies-literature
Unknown Neoadjuvant treatment for melanoma: current challenges and future perspectives.
| S-EPMC6094612 | biostudies-literature
Unknown Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review.
| S-EPMC4571784 | biostudies-literature